Fred B. Craves - May 14, 2024 Form 4 Insider Report for MADRIGAL PHARMACEUTICALS, INC. (MDGL)

Role
Director
Signature
/s/ Mardi Dier, as Attorney-in-Fact
Stock symbol
MDGL
Transactions as of
May 14, 2024
Transactions value $
-$2,470,560
Form type
4
Date filed
5/16/2024, 09:53 PM
Previous filing
Dec 11, 2023
Next filing
Jun 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MDGL Common Stock Options Exercise $1M +10K +2.42% $100.45 423K May 14, 2024 Direct
transaction MDGL Common Stock Options Exercise $1.31M +12.5K +2.95% $105.08 436K May 14, 2024 Direct
transaction MDGL Common Stock Sale -$1.86M -8.83K -2.03% $210.99 427K May 14, 2024 Direct F1, F2
transaction MDGL Common Stock Sale -$1.06M -5.01K -1.17% $211.84 422K May 14, 2024 Direct F1, F3
transaction MDGL Common Stock Sale -$290K -1.36K -0.32% $212.85 421K May 14, 2024 Direct F1, F4
transaction MDGL Common Stock Sale -$468K -2.19K -0.52% $213.85 418K May 14, 2024 Direct F1, F5
transaction MDGL Common Stock Sale -$387K -1.8K -0.43% $214.68 417K May 14, 2024 Direct F1, F6
transaction MDGL Common Stock Sale -$81K -375 -0.09% $216.08 416K May 14, 2024 Direct F1, F7
transaction MDGL Common Stock Sale -$156K -721 -0.17% $216.98 416K May 14, 2024 Direct F1, F8
transaction MDGL Common Stock Sale -$240K -1.1K -0.26% $217.86 414K May 14, 2024 Direct F1, F9
transaction MDGL Common Stock Sale -$219K -1K -0.24% $218.99 413K May 14, 2024 Direct F1, F10
transaction MDGL Common Stock Sale -$22K -100 -0.02% $219.90 413K May 14, 2024 Direct F1
holding MDGL Common Stock 1.26K May 14, 2024 See Footnotes F11
holding MDGL Common Stock 57.1K May 14, 2024 See Footnotes F12
holding MDGL Common Stock 18K May 14, 2024 See Footnotes F13

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MDGL Stock Option (right to buy) Options Exercise $0 -10K -100% $0.00* 0 May 14, 2024 Common Stock 10K $100.45 Direct F14
transaction MDGL Stock Option (right to buy) Options Exercise $0 -12.5K -100% $0.00* 0 May 14, 2024 Common Stock 12.5K $105.08 Direct F14
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 15, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $210.34 to $211.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $211.34 to $212.33, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.36 to $213.31 inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $213.36 to $214.34 inclusive.
F6 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.39 to $215.27 inclusive.
F7 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.61 to $216.58 inclusive.
F8 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.61 to $217.23 inclusive.
F9 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.64 to $218.37 inclusive.
F10 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.68 to $219.34 inclusive.
F11 These securities are held by Bay City Capital LLC ("BCC"). Dr. Craves disclaims beneficial ownership of these securities held by BCC, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such shares, except to the extent of his pecuniary interest, if any, in the securities by virtue of the limited liability company interests he owns in BCC.
F12 Represents shares held indirectly by Dr. Craves through a grantor retained annuity trust.
F13 Represents shares held indirectly by Dr. Craves through the Craves Family Foundation.
F14 The shares underlying this stock option are fully vested.

Remarks:

Exhibit 24 - Power of Attorney